Combination Therapies in Myelofibrosis with Dr. Lindsay Rein image

Combination Therapies in Myelofibrosis with Dr. Lindsay Rein

Sep 18, 2024
03:00PM - 04:00PM EDT
Online Event
Overview

The world of myelofibrosis treatment has been evolving for several years. Join us as we speak with Dr. Lindsay Rein about the exciting developments in combination therapies and how to determine if therapy option might be right for you. This is a wonderful opportunity to learn from, and ask questions to, a leading myelofibrosis specialist who is particularly interested in exploring newer treatments!

Highlights
Agenda
3:00 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and our featured speaker Lindsay Rein, MD 

3:05 PM
Presentation
Lindsay Rein, MD

Dr. Lindsay Rein talks about developments in combination therapies and how to determine if therapy option might be right for you.

3:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Lindsay Rein, MD

Lindsay Rein, MD

Dr. Lindsay Rein is an Associate Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke University where she sees and treats patients with various myeloproliferative neoplasms (MPNs). Dr. Rein leads a program of both early and late phase clinical trials for patients with MPNs and also led the recent establishment of a mastocytosis center of excellence at Duke for patients with systemic mastocytosis and associated mast cell disorders. She is a panel member for the NCCN guidelines for MPNs, systemic mastocytosis, and CML and is also a member of the H Jean Khoury Cure CML Consortium.